TITLE

New class of anti-HIV drug approved

PUB. DATE
June 2007
SOURCE
European Pharmaceutical Executive;Jun2007, p9
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the recommendation of the U.S. Food and Drug's (FDA) Antiviral Drugs Advisory Committee on the approval of Pfizer Inc.'s maraviroc, a chemokine receptor (CCR5) antagonist. It is designed to treat patients infected with CCR5-tropic human immunodeficiency virus-1 (HIV), which it prevents the virus from entering uninfected cells. Meanwhile, maraviroc is undergoing expedited regulatory review and if approved, it would be the first member of a new class of oral HIV medicines.
ACCESSION #
25938523

 

Related Articles

  • FDA panel OKs new class of HIV drug. Roehr, Bob // Bay Area Reporter;4/26/2007, Vol. 37 Issue 17, p17 

    The article reports that a committee of the U.S. Food and Drug Administration has recommended approval of Pfizer Inc.'s CCR5 inhibitor maraviroc, trademarked Celsentri. Maraviroc belongs to a class of anti-HIV drugs developed for heavily treatment-experienced patients. It works against the R5...

  • Boost for oral HIV treatment.  // European Pharmaceutical Executive;Sep2007, p14 

    The article reports on the approval by the U.S. Food and Drug Administration of Pfizer Inc.'s Selzentry tablets as the first in a new class of oral HIV medicines. The approval includes the recommendation of Selzentry as an antiretroviral treatment for adults who are infected with detectable...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Nov2008, Vol. 22 Issue 11, p917 

    The article offers news briefs related to developments related to antiviral agents. Pfizer Inc. has released data from a study of HIV patients, in which findings point to the need for proper patient selection prior to treatment with CCR5 therapies. The U.S. Food and Drug Administration (FDA)...

  • Enfuvirtide. Coleman, Craig I.; Musial, Bogdan L.; Ross, Jack // Formulary;Apr2003, Vol. 38 Issue 4, p204 

    Focuses on enfuvirtide, the first member of antiretrovirals to gain U.S. Food and Drug approval for the treatment of HIV-1 infection. Pharmacology; Pharmacokinetics; Clinical trials of enfuvirtide; Safety and tolerability; Drug interactions; Dosage and administration; Cost. INSET: Formulary...

  • OK for ddC.  // Advocate;11/2/93, Issue 641, p16 

    Cites the unanimous decision by the U.S. Food and Drugs Administration to recommend the approval for the use of the antiviral drug ddc as a single drug therapy against HIV.

  • Trends in the prescription drug plans delivering the Medicare Part D Prescription Drug Benefit. Brill, Joel V. // American Journal of Health-System Pharmacy;8/1/2007 Supplement, Vol. 64, pS3 

    Purpose. The potential impact of the Democrat-proposed Medicare drug program reform plan; possible Congressional actions in 2007; the standard Medicare prescription drug benefit; the use of low-income subsidies (LIS); and trends in 2006 and 2007 Medicare prescription drug plan (PDP) offerings,...

  • FDA approves maraviroc. Roehr, Bob // Bay Area Reporter;8/9/2007, Vol. 37 Issue 32, p17 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved Pfizer's Maraviroc, the first anti-HIV drug that targets the CCR5 coreceptor on the outside of the cell. The drug, under the trade name Selzentry, has been approved for use in treatment experienced patients. The...

  • New drugs and dosage forms.  // American Journal of Health-System Pharmacy;7/1/2006, Vol. 63 Issue 13, p1218 

    No abstract available.

  • Novel HIV treatment approved. Groeschen, Heather M.; Provost, George P. // American Journal of Health-System Pharmacy;9/15/2007, Vol. 64 Issue 18, p1886 

    The article reports on the announcement made by the U.S. Food and Drug Administration and Pfizer Inc. on the approval of Selzentry or maraviroc in August 2007. Selzentry is the first agent in a class of oral human immunodeficiency virus (HIV) medications such as chemokine receptor 5 (CCR5)...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics